By Tom Crosby, Marketing Manager, LSN
LSN’s partners at Venture Valuation recently released a “cluster report” in conjunction with KPMG. This report is targeted chiefly at North American and Asian life sciences companies looking to establish a presence in Europe. The analysis takes a deep look at the state of the European marketplace by examining the strength of bio-clusters in each of the six major EU countries for life sciences. This document is designed to serve as a guide for site selection, and details the particular strengths of each regional cluster – Here are a few highlights:
France:
- Focused on nutraceuticals and cosmetics.
- 60% of French life science companies undertake in-house R&D (highest % in EU).
Germany:
- Highest number of life science companies of any European country (focus on Medical Devices).
- Largest life science workforce in absolute numbers.
Ireland:
- Second largest LS workforce relative to the active population.
Netherlands:
- Attractive to regional HQs of non-domestic LS companies for their R&D activities.
Switzerland:
- Strong LS clusters with large number of global HQs of domestic companies.
- Largest number of regional HQs of non-domestic LS companies within the six countries covered.
United Kingdom:
- Europe’s largest cluster in Biotechnology Therapeutics and Pharmaceuticals.
- Strong in R&D and a large life science workforce.
To read the full 46 page report that details the evaluation of these regions, please click here
Next Phase Newsletter 
Leave a comment